AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer

Sponsor
The Netherlands Cancer Institute
Study ID
NCT03147040
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Carboplatin — DRUG
    Chemotherapy treatment with carboplatin and atezolizumab
  • Atezolizumab — DRUG
    Chemotherapy treatment with carboplatin and atezolizumab

Study Details

This is a single arm multicenter non-randomized phase II trial testing the efficacy of the combination of carboplatin plus atezolizumab in metastatic ILC

Key Dates

Start date
Nov 2, 2017
Status verified
Jul 2022
Primary completion
May 1, 2022
Completion
Jul 1, 2022

Study Design

Enrollment
23 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Carboplatin/Atezolizumab
    Carboplatin AUC=1.5, weekly schedule, maximum 12 administrations Atezolizumab, 1200 mg flat dose, 3-weekly schedule, starting after two administrations of carboplatin

Primary Outcome Measure

Number of patients free of progression at 6 months [ Time Frame: At 6 months ]

Related Studies